Lundbeck buying Northera maker Chelsea for up to $658m
This article was originally published in Scrip
Executive Summary
Lundbeck will strengthen its neurology portfolio by paying $530m up front for Chelsea Therapeutics, whose drug Northera (droxidopa) is approved and waiting for a company to take charge of commercialization.